study to assess the safety and tolerability of the Tor Kinase Inhibitor AZD8055
Study identifier:D1600C00003
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, open label, single-centre study to assess the safety and tolerability of the Tor Kinase Inhibitor AZD8055 administered orally to Japanese patients with advanced solid tumours
Medical condition
cancer
Phase
Phase 1
Healthy volunteers
No
Study drug
AZD8055
Sex
All
Actual Enrollment
19
Study type
Interventional
Age
20 Years +
Date
Study Start Date: 01 Aug 2009
Primary Completion Date: 01 Dec 2010
Study Completion Date: 01 Dec 2010
Study design
Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: AZD8055 AZD8055 will be administered orally | Drug: AZD8055 Tablets, orally administered, twice daily |
Contacts
Investigators
Principal Investigator
Ian Smith
AstraZeneca
